Polyamines, natural molecules found in every living cell and increasingly popular as anti-aging supplements, appear to operate through two distinct biological pathways — one that supports healthy aging and another that accelerates cancer growth. Researchers at Tokyo University of Science have now identified the molecular mechanism behind this split behavior, offering the clearest explanation yet for a contradiction that has puzzled scientists for years.
The study, published in Volume 301, Issue 8 of the Journal of Biological Chemistry, centers on how polyamines interact with two closely related proteins: eIF5A1 and eIF5A2. Though the two proteins share 84% of their amino acid sequence, they drive fundamentally different outcomes depending on the cellular environment.
What Polyamines Actually Do
In normal, healthy cells, polyamines activate eIF5A1, which stimulates autophagy, the process by which cells clear out damaged components. This is the pathway associated with longevity benefits, particularly those linked to the polyamine compound spermidine. The chain of events supports mitochondrial health and cellular maintenance.
In cancer cells, the picture changes entirely. Polyamines elevate levels of eIF5A2 instead, which then controls gene expression to drive rapid cell proliferation. The energy source also shifts. Rather than supporting mitochondrial respiration, polyamines in cancer cells primarily boost glycolysis, a faster process that converts glucose into energy to feed tumor growth.
That distinction matters. It means the same compound that promotes longevity in healthy tissue is effectively turbocharging a different set of biological machinery in cancer cells.
How the Research Was Conducted
The team, led by Associate Professor Kyohei Higashi from the Faculty of Pharmaceutical Sciences, worked with human cancer cell lines and used a controlled experimental approach. Researchers first depleted polyamine levels using a drug, then restored them by introducing spermidine. This allowed them to isolate and measure the direct effects of polyamines on cancer cell behavior.
Using high-resolution proteomic analysis, the team tracked changes across more than 6,700 proteins. Their data showed polyamines specifically elevated eIF5A2 and five ribosomal proteins, including RPS27A, RPL36AL, and RPL22L1, all of which are associated with cancer severity.
Two Nearly Identical Proteins, Opposite Outcomes
“The biological activity of polyamines via eIF5A differs between normal and cancer tissues,” said Dr. Higashi. “In normal tissues, eIF5A1, activated by polyamines, activates mitochondria via autophagy, whereas in cancer tissues, eIF5A2, whose synthesis is promoted by polyamines, controls gene expression at the translational level to facilitate the proliferation of cancer cells.”
The 84% sequence similarity between the two proteins had long obscured why they behave so differently. This research provides a functional explanation: context determines which protein takes precedence, and that context has significant consequences.
Implications for Supplement Use and Drug Development
The findings raise important questions about polyamine supplementation, which has grown in popularity within longevity and wellness communities. While the research does not establish that supplements cause cancer, it does establish a credible mechanism by which elevated polyamine levels could support tumor progression in cancer cells that are already present.
On the drug development side, the identification of eIF5A2 as a cancer-specific driver, operating through a pathway distinct from eIF5A1, opens a potential avenue for targeted therapies that could disrupt tumor metabolism without interfering with the protective functions polyamines serve in healthy tissue.
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
This article is a curated summary based on third-party sources. Source: Read the original article
